<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096290</url>
  </required_header>
  <id_info>
    <org_study_id>09-250</org_study_id>
    <nct_id>NCT01096290</nct_id>
  </id_info>
  <brief_title>Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications</brief_title>
  <official_title>Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Alabama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sucampo Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Alabama</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Constipation from medications is a serious and common condition. Lubiprostone has properties&#xD;
      that make it a candidate drug. One hundred volunteers with constipation who are taking&#xD;
      medications known to cause constipation will be randomized to take lubiprostone or placebo&#xD;
      for 28 days. Therapeutic outcome will be evaluated by investigator and study subject&#xD;
      assessment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lubiprostone is a novel chloride channel activator that increases intestinal fluid secretion&#xD;
      and motility. It is FDA approved and indicated for treatment of chronic idiopathic&#xD;
      constipation and recently, constipation-predominant irritable bowel syndrome.&#xD;
&#xD;
      The Physicians Desk Reference lists over 90 Brand medications with reported incidence&#xD;
      associated with constipation over 3%. Little data are available about treatment responses. A&#xD;
      recent publication by our group reported treatment success for medication constipation using&#xD;
      polyethylene glycol. Since ongoing studies are addressing the role of lubiprostone in opioid&#xD;
      constipation, this work will be enrolling medication constipation study subjects not using&#xD;
      opioids.&#xD;
&#xD;
      In this study, patients who meet diagnostic criteria for constipation will be randomized to&#xD;
      receive 28 days of treatment with lubiprostone 24mcg twice a day. Data will be collected to&#xD;
      evaluate therapeutic outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Number of needed participants could not be obtained&#xD;
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relief of Constipation Defined by Modified ROME Criteria</measure>
    <time_frame>30 days</time_frame>
    <description>Subjects will report symptoms by questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency</measure>
    <time_frame>30 days</time_frame>
    <description>Subjects will report stool frequency by questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Lubiprostone 24mcg BID for 30 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, matched, blinded</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lubiprostone</intervention_name>
    <description>24mcg BID, capsule, oral 30days</description>
    <arm_group_label>Lubiprostone 24mcg BID for 30 days</arm_group_label>
    <other_name>Amitiza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched placebo</intervention_name>
    <description>Twice daily for 30days, oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo, sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male or female outpatient age 19 or older.&#xD;
&#xD;
          -  Patients meet International Congress of Gastroenterology (ROME III) clinical criteria&#xD;
             for constipation*:&#xD;
&#xD;
               1. Must include two or more of the following:&#xD;
&#xD;
                    1. Straining in &gt; 1/4 defecations;&#xD;
&#xD;
                    2. Lumpy or hard stools &gt; 1/4 defecations;&#xD;
&#xD;
                    3. Sensation of incomplete evacuation in 1/4 defecations;&#xD;
&#xD;
                    4. Sensation of anorectal obstruction/blockage in &gt; 1/4 defecations;&#xD;
&#xD;
                    5. &lt;3 defecations/week.&#xD;
&#xD;
               2. Loose stools are rarely present without the use of laxatives.&#xD;
&#xD;
               3. There are insufficient criteria for irritable bowel syndrome. *Criteria fulfilled&#xD;
                  for the last 3 months with symptom onset at least 6 months prior to diagnosis.&#xD;
&#xD;
          -  Use of one or more of listed medications known to cause constipation.&#xD;
&#xD;
          -  If female and of childbearing potential, patient must be surgically sterilized or&#xD;
             using oral contraceptives, depot contraceptives, intrauterine device, or testifies&#xD;
             that she is monogamous with a vasectomized partner, or practices abstinence and will&#xD;
             continue to do so during the duration of study. Mandatory compliance is required.&#xD;
             Serum pregnancy tests will be performed at screening and during needed follow-up.&#xD;
             Negative results will be received before inclusion and administration of first study&#xD;
             dose. If pregnancy occurs during the trial, the investigator is notified immediately&#xD;
             resulting in prompt discontinuation.&#xD;
&#xD;
          -  Study subjects must not have received lubiprostone for more than 72 hours.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected obstruction, gastric retention, ileus, perforation, fecal impaction&#xD;
             or inflammatory bowel disease.&#xD;
&#xD;
          -  Severe diarrhea.&#xD;
&#xD;
          -  Prior small bowel or colonic resection or colostomy.&#xD;
&#xD;
          -  Weight &lt; 80 lbs.&#xD;
&#xD;
          -  If the patient has constipation that according to the investigator's clinical judgment&#xD;
             is not the result of constipating medications but is suffering from a secondary cause&#xD;
             including but limited to factors that are dietary, neurologic, congenital, diabetic or&#xD;
             hypothyroid.&#xD;
&#xD;
          -  Positive stool hemoccult (Can be included if colonoscopic evaluation is subsequently&#xD;
             negative).&#xD;
&#xD;
          -  Significant cardiac, renal or hepatic insufficiency.&#xD;
&#xD;
          -  Pregnant or expecting to become pregnant within 120 days of study enrollment.&#xD;
&#xD;
          -  Lactating or breast feeding.&#xD;
&#xD;
          -  Subjects using opioid medications.&#xD;
&#xD;
          -  Subjects who in the opinion of the investigator would be unable to comply adequately&#xD;
             with the study plan.&#xD;
&#xD;
          -  Use of investigational drugs in the last 30 days.&#xD;
&#xD;
          -  Patients with known allergy to lubiprostone.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack A DiPalma, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Alabama College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USA Pavilion at Infirmary West</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36693</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 22, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2010</study_first_posted>
  <results_first_submitted>December 1, 2017</results_first_submitted>
  <results_first_submitted_qc>August 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2020</results_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>constipation</keyword>
  <keyword>lubiprostone</keyword>
  <keyword>healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lubiprostone 24mcg BID for 30 Days</title>
          <description>Active medication&#xD;
lubiprostone: 24mcg BID, capsule, oral 30days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo, matched, blinded&#xD;
Matched placebo: Twice daily for 30days, oral</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lubiprostone 24mcg BID for 30 Days</title>
          <description>Active medication&#xD;
lubiprostone: 24mcg BID, capsule, oral 30days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo, matched, blinded&#xD;
Matched placebo: Twice daily for 30days, oral</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relief of Constipation Defined by Modified ROME Criteria</title>
        <description>Subjects will report symptoms by questionnaire</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24mcg BID for 30 Days</title>
            <description>Active medication&#xD;
lubiprostone: 24mcg BID, capsule, oral 30days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, matched, blinded&#xD;
Matched placebo: Twice daily for 30days, oral</description>
          </group>
        </group_list>
        <measure>
          <title>Relief of Constipation Defined by Modified ROME Criteria</title>
          <description>Subjects will report symptoms by questionnaire</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency</title>
        <description>Subjects will report stool frequency by questionnaire</description>
        <time_frame>30 days</time_frame>
        <population>Data was not collected for this Outcome Measure</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24mcg BID for 30 Days</title>
            <description>Active medication&#xD;
lubiprostone: 24mcg BID, capsule, oral 30days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, matched, blinded&#xD;
Matched placebo: Twice daily for 30days, oral</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency</title>
          <description>Subjects will report stool frequency by questionnaire</description>
          <population>Data was not collected for this Outcome Measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening visit 1 to Follow-up Day 56</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lubiprostone 24mcg BID for 30 Days</title>
          <description>Active medication&#xD;
lubiprostone: 24mcg BID, capsule, oral 30days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, matched, blinded&#xD;
Matched placebo: Twice daily for 30days, oral</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>100 participants were needed to obtain statistical power. Only 23 participants were enrolled. Therefore, data analysis was not completed since a success rate could not be adequately demonstrated on such a small sample.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jack DiPalma, MD</name_or_title>
      <organization>University of South Alabama</organization>
      <phone>251-660-5555</phone>
      <email>jdipalma@health.southalabama.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

